Medical Cost and Healthcare Resource Utilization Influenced by Anti-Platelet Agent Selection in Patients with Acute Coronary Syndrome

Acute coronary syndrome (ACS), after receiving percutaneous coronary intervention (PCI), requires appropriate long-term antiplatelet therapy with a P2Y12 combination with aspirin.[1,2] Clopidogrel, a 2nd generation P2Y12 antagonist, has stood as the gold-standard, but two alternative options, prasugrel and ticagrelor, are now available in the US healthcare market. Multiple studies retrospectively analyzed and compared outcomes of different anti-platelet strategies in real-world ACS populations using administrative databases. However, due to methodological limitations, the studies potentially overestimated overall cost or did not account for the adherence on the initial treatment.